Transgenic mice that overexpress the anti-apoptotic protein Bcl-2 demonstrate decreased myocyte apoptosis and improved survival following ischemic injury.[73] Therefore, interventions aimed at targeting apoptotic pathways may represent a promising therapeutic strategy to mitigate myocyte loss and preserve cardiac function in patients with CHD. The gene discussed is BCL2; the disease is coronary artery disorder.